Bunkerhill Health receives FDA clearance for an AI model that detects mitral annular calcification (MAC) on routine, non-gated CT scans.
Key Details
- 1Bunkerhill Health’s AI model (Bunkerhill MAC) is FDA-cleared to detect and evaluate MAC.
- 2The tool works on routine, non-gated CT scans, expanding accessibility for cardiovascular risk detection.
- 3This is the first FDA-approved AI specifically for MAC identification.
- 4Development included data from over 25 academic medical centers, including Stanford University.
- 5The algorithm is integrated into Carebricks, Bunkerhill Health’s generative AI platform.
Why It Matters
This clearance introduces a new, scalable AI solution to consistently identify a cardiovascular risk marker that can be missed in routine practice, potentially improving patient care and research. Automating MAC detection could significantly impact cardiovascular and structural heart disease assessments in radiology workflows.
Source
Cardiovascular Business
Related News
•AuntMinnie
AI Triage Tool Speeds Up ICH Head CT Turnaround in ED
AI-based triage for intracranial hemorrhage on head CT reduced emergency department report turnaround by 13 minutes.
•Cardiovascular Business
FDA Clears Elucid's AI-Driven FFR-CT Solution for Cardiac Imaging
Elucid's FFR-IQ, an AI-powered noninvasive FFR-CT tool, receives FDA clearance for clinical use.
•Radiology Business
FDA Approves SimBioSys AI Tool for Breast Cancer Risk via MRI
SimBioSys received FDA clearance for TumorSight Risk, an AI tool assessing breast cancer recurrence risk using MRI.